Welcome to I.ON, the on-demand digital immunology programme designed to provide rheumatologists, dermatologists, immunologists and allergists treating PsO, chronic spontaneous urticaria, psoriatic arthritis and axial spondyloarthritis with first-class medical educational content.


What is PsA?

PsA is a type of inflammatory arthritis which affects approximately a quarter of the population. It is a heterogeneous disorder associated with disability, skin disease, joint damage and in severe cases, premature mortality. PsA is irreversible and progressive, and the process of joint damage begins immediately.1

Up to 41% of patients with psoriasis develop PsA, which in turn can lead to severely impaired physical functioning, ability to work and quality of life.2–7


PsA, psoriatic arthritis.



  1. McArdle A, et al. Clin Rev Allergy & Immunol 2018;55:271–294.
  2. Rosen CF, et al. Rheumatology (Oxford) 2012;51:571–576.
  3. Gladman DD, et al.  J Rheumatol 1990;17:809–812.
  4. McHugh NJ, et al. Rheumatology (Oxford) 2003;42:778–783.
  5. Reich K, et al. Br J Dermatol 2009;160:1040–1047.
  6. Villani AP, et al. J Am Acad Dermatol 2015;73:242–248.
  7. Mease PJ, et al. J Am Acad Dermatol 2013;69:729–735.
Rate this content: 
No votes yet
UK | October 2021 | 146366

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]